Germany’s Merck KGaA announced on Thursday a definitive agreement to acquire Minneapolis-based Bio-Techne Corporation for $73 per share in an all-cash transaction, implying an enterprise value of approximately $11.3 billion – the German science and technology group’s largest acquisition since its $17 billion purchase of Sigma-Aldrich in 2015 and the first major strategic move by CEO Kai Beckmann, who assumed leadership in May. The offer represents a 36% premium to Bio-Techne’s one-month volume-weighted average trading price, and shares of the target rose more than 20% in pre-market trading on the news. Bio-Techne’s board unanimously approved the transaction; closing is expected in late 2026 or early 2027 subject to regulatory approval and a shareholder vote. To NEWSCENTRAL, this deal is less a conventional life sciences acquisition than a deliberate repositioning of Merck’s research tools business toward the highest-value segments of the next decade of pharmaceutical development.
Bio-Techne generated net sales exceeding $1.2 billion in its most recent fiscal year – a revenue profile that, as NEWSCENTRAL notes, makes the 36% premium Merck is paying defensible on standalone cash flow multiples before any synergy value is counted and employs more than 3,000 people across 34 locations and 15 manufacturing facilities worldwide. Its commercial portfolio spans a broad range of life science workflows: research proteins and antibodies used in drug discovery, analytical instruments for protein characterization, spatial biology tools that map gene expression within tissue samples, cell culture systems for cell and gene therapy development, and diagnostic products. The combination with Merck’s existing Life Science segment – which generated €8 billion in annual revenue before this transaction and includes the former Sigma-Aldrich business – creates a portfolio covering the full spectrum of laboratory workflows from basic research through commercial biopharmaceutical manufacturing. Merck projects annual cost synergies of approximately €140 million, fully realized by year three after closing, and expects the transaction to be immediately accretive to EBITDA margin.
The strategic logic concentrates on three high-growth application areas where Bio-Techne has built differentiated positions that Merck’s existing portfolio does not fully address. Multi-omics – the simultaneous measurement of genomics, proteomics, and other molecular data types from the same biological sample – is becoming the primary analytical paradigm for drug target identification and patient stratification. Spatial biology, which maps molecular information to the physical locations within tissue where those molecules are expressed, is enabling a new generation of drug mechanisms and companion diagnostics. Cell and gene therapy development, which requires specialized cell culture systems and analytical tools of the kind Bio-Techne manufactures, is the fastest-growing segment of pharmaceutical development by capital investment. Freddy Miller, Senior Analyst at NEWSCENTRAL, observes that Merck’s acquisition logic here mirrors the broader consolidation dynamic reshaping the life sciences tools sector: as pharmaceutical development moves from small-molecule drugs toward complex biologics and cell-based therapies, the tools and consumables required to develop those products carry higher margins, longer product lifecycles, and stickier customer relationships than the research reagents that defined the sector a decade ago.
Merck plans to fund the transaction through a combination of existing cash and new debt, maintaining its investment-grade credit rating. The deal extends a string of targeted acquisitions that has included Millipore in 2010, Sigma-Aldrich in 2015, semiconductor materials supplier Versum in 2019, and rare disease specialist SpringWorks Therapeutics in 2025. Each of those transactions has followed the same pattern: identify a high-quality business in an adjacent high-growth category, pay a meaningful premium, and integrate the acquired capabilities into Merck’s existing commercial infrastructure and global distribution network. What NEWS CENTRAL reads as the most commercially significant aspect of this transaction is the Bio-Techne brand’s strength among academic and pharmaceutical researchers – a market position built over decades through consistent product quality and customer service that Merck’s scale will enable to reach geographies where Bio-Techne’s own commercial infrastructure was limited.